Specialty Sections From CHEST® Physician
Networks
Use of 6-minute walk distance as a clinical trial outcome in interstitial lung disease
Pulmonary arterial hypertension (PH) and more recently interstitial lung disease (ILD) trials use the 6-minute walk test (6MWT) as a primary...
Networks
Now we have MERCY
Beta-lactam antibiotics, including penicillin, carbapenems, and cephalosporins, exhibit time-dependent bacterial eradication.
Pulmonary Perspectives®
Home oxygen therapy: What does the data show?
Chronic obstructive pulmonary disease is the most common reason for the prescription of long-term oxygen therapy.
Networks
Environmental and occupational risk factors for lung cancer
Lung cancer is the third most prevalent cancer in United States, with the highest mortality.
Networks
PalliPulm: Time to expand our arsenal
Symptoms at the end of life in patients with COPD are just as severe as in patients with advanced cancer.
Networks
Hot or cold – impact on asthma and COPD
Sleep Strategies
Implementing a hypoglossal nerve stimulation program in your sleep practice
Nearly 50% of CPAP users discontinue treatment by the fifth year.
Networks
Sepsis-induced cardiomyopathy: Is it time to establish a standard of care?
Sepsis and septic shock still carry high morbidity and mortality in ICU patients despite recent improvements in care.
Critical Care Commentary
Celebrating the inaugural issues of CHEST’s new open access journals
After much anticipation, the inaugural issues of both CHEST® Critical Care and CHEST® Pulmonary officially launched in late June.
Pulmonary Perspectives®
Which biologic therapy should I use in patients who have moderate to severe asthma with associated comorbidities?
As new treatments for specific moderate to severe asthma phenotypes have been developed, management decisions have grown more complicated.